A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study
Phase of Trial: Phase III
Latest Information Update: 27 Aug 2017
At a glance
- Drugs Ibrutinib (Primary)
- Indications Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Lymphoid leukaemia; Mantle-cell lymphoma
- Focus Adverse reactions
- Sponsors Janssen Research & Development
- 27 Jul 2017 Planned End Date changed from 31 Dec 2024 to 1 Jan 2025.
- 11 Jan 2017 Planned End Date changed from 1 Dec 2021 to 1 Dec 2024.
- 19 May 2016 Planned number of patients changed from 200 to 700.